CoChat

Lack of effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on psoriasis in glucose‐tolerant patients – a randomized placebo‐controlled trial

Faurschou, A., Gyldenløve, M., Rohde, U., Thyssen, J.P., Zachariae, C., Skov, L., Knop, F.K., Vilsbøll, T. · 2015 · Journal of the European Academy of Dermatology and Venereology
Cited by 89

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background: It has been proposed that glucagon‐like peptide‐1 receptor (GLP‐1R) agonists used for the treatment of patients with type 2 diabetes might also improve their psoriasis. Objective: To assess the efficacy and safety of the GLP‐1R agonist liraglutide in glucose‐tolerant patients with plaque psoriasis. Methods: A total of 20 obese (body mass index > 25 kg/m 2), glucose‐tolerant patients with plaque psoriasis (psoriasis area and severity index (PASI) of at least 8) were randomized 1 : 1 to once‐daily subcutaneous injections with liraglutide or placebo for an 8‐week period. The primary end points were improvement in PASI and dermatology life quality index (DLQI). Secondary end points included changes in weight and high sensitive C‐reactive protein (hs CRP) levels, as well as adverse events. Results: After 8 weeks of treatment, no significant change in PASI was found in the liraglutide group (mean±standard deviation: −2.6 ± 2.1) compared with the placebo group (−1.3 ± 2.4) (P = 0.228). No difference in DLQI was observed between the groups [−2.5 ± 4.4 (liraglutide) vs. −3.7 ± 4.8 (placebo); P = 0.564]. Hs CRP did not change in any of the groups (0.26 ± 1 (placebo) vs. 0.25 ± 2.2 (liraglutide); P = 0.992). Liraglutide treatment resulted in a bodyweight loss of 4.7 ± 2.5 kg compared with 1.6 ± 2.7 kg in the placebo group (P = 0.014) accompanied by decreased cholesterol levels. No serious adverse events occurred during the 8‐week observation period. The most common complaint was transient nausea, which occurred in 45% of the liraglutide‐treated patients but in none from the placebo group. Conclusion: Liraglutide treatment for 8 weeks did not significantly change PASI, DLQI, or hs CRP in a small group of glucose‐tolerant obese patients with plaque psoriasis compared with placebo. A significant weight loss and decrease in cholesterol levels was observed in liraglutide‐treated patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdv.12629

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 14

  1. 10.2337/dc12-2330 · DOI
  2. 10.1001/archinte.167.15.1670 · DOI · Paper page
  3. 10.1111/j.1365-2796.2010.02310.x · DOI · Paper page
  4. 10.1016/B978-0-12-381517-0.00015-1 · DOI
  5. 10.1016/j.diabet.2011.11.004 · DOI
  6. 10.1111/j.1468-3083.2012.04609.x · DOI · Paper page
  7. 10.1111/bjd.12886 · DOI · Paper page
  8. 10.1111/exd.12081 · DOI · Paper page
  9. Reid CT, 2013, Liraglutide in combination with acitretin for severe recalcitrant psoriasis, Br J Dermatol, 169, 181
  10. 10.1001/jamadermatol.2013.722 · DOI · Paper page
  11. 10.1007/s00018-010-0396-5 · DOI
  12. 10.1016/j.bbrc.2009.10.015 · DOI · Paper page
  13. 10.1016/j.mehy.2011.09.011 · DOI
  14. 10.1161/01.CIR.0000132467.45278.59 · DOI · Paper page

Cited by

See all 89

Metadata

Authors
Faurschou, A., Gyldenløve, M., Rohde, U., Thyssen, J. P., Zachariae, C., Skov, L., Knop, F. K., & Vilsbøll, T.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2014-08-20
Volume
29
Issue
3
Pages
555-559
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W2109769875
Cited by
89
References
11
FWCI
1.04
Type
journal article
Language
en
Open access
closed
Funders
  • Novo Nordisk
  • Aage Bangs Fond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.